P223 C-reactive protein improvement after vedolizumab induction phase is associated with remission after 6 months of treatment in ulcerative colitis patients

Abstract

Background: Vedolizumab, a gut-selective anti-integrin inhibitor is a biologic agent indicated for ulcerative colitis (UC) treatment. We retrospectively investigated whether improvement of serum C-reactive protein (CRP) levels, after the first 3 infusions of vedolizumab (induction phase) predicts responsiveness at 6 months of therapy. Methods: Adult UC patients followed at a tertiary IBD center and treated with vedolizumab were included. Cumulative rates of clinical remission (CR, partial Mayo score